


# Immunity to Infectious Diseases

BIOS 486A/586A  
K.J.Goodrum 2005

## Topic Outline


- Routes and sites of infection
- Mechanisms of tissue injury in infection
- Timing of immune responses to infection
- Regulation of cell-mediated ( $T_H1$ ) vs. humoral immunity ( $T_H2$ ) in infections
- Effector mechanisms for immunity to different pathogens
- Microbial evasion of immune responses
- Immunizations/vaccines

**Primary Route of Infection: Microbial Adherence and Invasion of epithelial tissues (lung, gut, other)**



Janeway, Fig. 10.2

**Primary Route of Infection: Microbial Adherence and Invasion of epithelial tissues (continued).**



Janeway, Fig. 10.2

Figure 10-2 part 2 of 2 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.4. Infection compartments

|                     | Extracellular  |  | Intracellular   |  |
|---------------------|--|--|---|--|
|                     | Interstitial spaces, blood, lymph                          | Epithelial surfaces  | Cytoplasmic   | Vesicular  |
| Site of infection   |  |  |   |  |
| Organisms           | Viruses<br>Bacteria<br>Protozoa<br>Fungi<br>Worms          | <i>Neisseria gonorrhoeae</i><br><i>Mycoplasma</i> spp.<br><i>Streptococcus pneumoniae</i><br><i>Vibrio cholerae</i><br><i>Escherichia coli</i><br><i>Helicobacter pylori</i><br><i>Candida albicans</i><br>Worms | Viruses<br><i>Chlamydia</i> spp.<br><i>Rickettsia</i> spp.<br><i>Listeria monocytogenes</i><br>Protozoa | <i>Mycobacterium</i> spp.<br><i>Salmonella typhimurium</i><br><i>Yersinia pestis</i><br><i>Listeria</i> spp.<br><i>Legionella pneumophila</i><br><i>Cryptococcus neoformans</i><br><i>Histoplasma</i><br><i>Leishmania</i> spp.<br><i>Trypanosoma</i> spp. |
| Protective immunity | Antibodies<br>Complement<br>Phagocytosis<br>Neutralization | Antibodies, especially IgA<br>Antimicrobial peptides   | Cytotoxic T cells<br>NK cells   | T-cell and NK-cell dependent macrophage activation   |

Figure 10-4 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.5. Mechanisms of Pathogen-induced tissue Damage

|                      | Direct mechanisms of tissue damage by pathogens  |   |   |
|----------------------|--|---|---|
|                      | Exotoxin production  | Endotoxin   | Direct cytopathic effect  |
| Pathogenic mechanism |  |   |   |
| Infectious agent     | <i>Streptococcus pyogenes</i><br><i>Staphylococcus aureus</i><br><i>Corynebacterium diphtheriae</i><br><i>Clostridium tetani</i><br><i>Vibrio cholerae</i> | <i>Escherichia coli</i><br><i>Haemophilus influenzae</i><br><i>Salmonella typhi</i><br><i>Shigella</i><br><i>Pseudomonas aeruginosa</i><br><i>Yersinia pestis</i> | Varicella-zoster virus<br>Hepatitis B virus<br>Polio virus<br>Measles virus<br>Influenza virus<br>Herpes simplex virus<br>Human herpes virus 8 (HHV8)         |
| Disease              | Tonsillitis, scarlet fever<br>Boils, toxic shock syndrome, food poisoning<br>Diphtheria<br>Tetanus<br>Cholera  | Gram-negative sepsis<br>Meningitis, pneumonia<br>Typhoid<br>Bacillary dysentery<br>Wound infection<br>Plague  | Smallpox<br>Chickenpox, shingles<br>Hepatitis<br>Poliomyelitis<br>Measles, subacute sclerosing panencephalitis<br>Influenza<br>Cold sores<br>Kaposi's sarcoma |

Figure 10-5 part 1 of 2 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.5. Mechanisms of Pathogen-induced tissue Damage (continued)




| Pathogenic mechanism  | Indirect mechanisms of tissue damage by pathogens  |  |   |
|---|--|--|---|
|   | Immune complexes   | Anti-host antibody   | Cell-mediated immunity  |
|  |   |  |   |
| <b>Infectious agent</b>   | Hepatitis B virus<br>Malaria<br>Streptococcus pyogenes<br>Treponema pallidum<br>Most acute infections                        | Streptococcus pyogenes<br>Mycoplasma pneumoniae                                    | Mycobacterium tuberculosis<br>Mycobacterium leprae<br>Lymphocytic choriomeningitis virus<br>Borrelia burgdorferi<br>Schistosoma mansoni<br>Herpes simplex virus |
| <b>Disease</b>  | Kidney disease<br>Vascular deposits<br>Glomerulonephritis<br>Kidney damage in secondary syphilis<br>Transient renal deposits | Rheumatic fever<br>Hemolytic anemia  | Tuberculosis<br>Tuberculoid leprosy<br>Aseptic meningitis<br>Lyme arthritis<br>Schistosomiasis<br>Herpes stromal keratitis                                      |

Figure 10-5 part 2 of 2 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.1. Time course of immune response to acute infection.




Figure 10-1 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig.10.9. Infection induced Th1 vs. Th2 responses.




Figure 10-9 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.17. Protective Effector Mechanisms against various infectious microbes

|         | Infectious agent             | Disease       | Humoral immunity |     |     |     | Cell-mediated immunity    |                    |
|---------|------------------------------|---------------|------------------|-----|-----|-----|---------------------------|--------------------|
|         |                              |               | IgM              | IgG | IgE | IgA | CD4 T cells (macrophages) | CD8 killer T cells |
| Viruses | Variola                      | Smallpox      | □                | □   | □   | □   | ▤                         | ▥                  |
|         | Varicella zoster             | Chickenpox    | ▤                | ▥   | □   | □   | □                         | ▥                  |
|         | Epstein-Barr virus           | Mononucleosis | □                | ▥   | □   | □   | □                         | ▥                  |
|         | Influenza virus              | Influenza     | □                | ▥   | □   | ▤   | □                         | ▥                  |
|         | Mumps virus                  | Mumps         | □                | ▥   | □   | □   | □                         | ▥                  |
|         | Measles virus                | Measles       | □                | ▥   | □   | □   | □                         | ▥                  |
|         | Polio virus                  | Poliomyelitis | □                | ▥   | □   | □   | □                         | ▥                  |
|         | Human immunodeficiency virus | AIDS          | □                | ▥   | □   | □   | □                         | ▥                  |

Figure 10-17 part 1 of 3 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.17. Protective Effector Mechanisms against various infectious microbes (continued)

|              | Infectious agent                   | Disease               | Humoral immunity |     |           |     | Cell-mediated immunity    |                    |
|--------------|------------------------------------|-----------------------|------------------|-----|-----------|-----|---------------------------|--------------------|
|              |                                    |                       | IgM              | IgG | IgE       | IgA | CD4 T cells (macrophages) | CD8 killer T cells |
| Bacteria     | <i>Staphylococcus aureus</i>       | Boils                 |                  |     |           |     |                           |                    |
|              | <i>Streptococcus pyogenes</i>      | Tonsillitis           |                  |     |           |     |                           |                    |
|              | <i>Streptococcus pneumoniae</i>    | Pneumonia             |                  |     |           |     |                           |                    |
|              | <i>Neisseria gonorrhoeae</i>       | Gonorrhea             |                  |     |           |     |                           |                    |
|              | <i>Neisseria meningitidis</i>      | Meningitis            |                  |     |           |     |                           |                    |
|              | <i>Corynebacterium diphtheriae</i> | Diphtheria            |                  |     |           |     |                           |                    |
|              | <i>Clostridium tetani</i>          | Tetanus               |                  |     |           |     |                           |                    |
|              | <i>Treponema pallidum</i>          | Syphilis              |                  |     | Transient |     |                           |                    |
|              | <i>Borrelia burgdorferi</i>        | Lyme disease          |                  |     | Transient |     |                           |                    |
|              | <i>Salmonella typhi</i>            | Typhoid               |                  |     |           |     |                           |                    |
|              | <i>Vibrio cholerae</i>             | Cholera               |                  |     |           |     |                           |                    |
|              | <i>Legionella pneumophila</i>      | Legionnaire's disease |                  |     |           |     |                           |                    |
|              | <i>Rickettsia prowazekii</i>       | Typhus                |                  |     |           |     |                           |                    |
|              | <i>Chlamydia trachomatis</i>       | Trachoma              |                  |     |           |     |                           |                    |
| Mycobacteria | Tuberculosis, leprosy              |                       |                  |     |           |     |                           |                    |


Figure 10-17 part 2 of 3 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.17. Protective Effector Mechanisms against various infectious microbes (continued)


|          | Infectious agent         | Disease         | Humoral immunity |     |     |     | Cell-mediated immunity    |                    |
|----------|--------------------------|-----------------|------------------|-----|-----|-----|---------------------------|--------------------|
|          |                          |                 | IgM              | IgG | IgE | IgA | CD4 T cells (macrophages) | CD8 killer T cells |
| Fungi    | <i>Candida albicans</i>  | Candidiasis     |                  |     |     |     |                           |                    |
| Protozoa | <i>Plasmodium</i> spp.   | Malaria         |                  |     |     |     |                           |                    |
|          | <i>Toxoplasma gondii</i> | Toxoplasmosis   |                  |     |     |     |                           |                    |
|          | <i>Trypanosoma</i> spp.  | Trypanosomiasis |                  |     |     |     |                           |                    |
|          | <i>Leishmania</i> spp.   | Leishmaniasis   |                  |     |     |     |                           |                    |
| Worms    | Schistosome              | Schistosomiasis |                  |     |     |     |                           |                    |

Figure 10-17 part 3 of 3 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.23. Mucosal  $\gamma\delta$ T cell function.



Janeway. Fig. 10.24. Mucosal Secretory IgA function



Janeway. Fig. 10.27. Recognition of intracellular infection by Nod1.




Figure 10-27 part 1 of 2 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 10.27. Recognition of intracellular infection by Nod1.(continued)








Figure 10-27 part 2 of 2 Immunobiology, 6/e. (© Garland Science 2005)









Janeway. Fig. 9.1. Protective effector mechanisms of antibody.



Janeway. Fig. 1.24 Protective effector mechanisms of antibody.





Janeway. Fig. 11.2. Immune Evasion via antigen drift/shift.




Figure 11-2 part 1 of 2 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 11.2. Immune Evasion via antigen drift/shift. (continued)






Figure 11-2 part 2 of 2 Immunobiology, 6/e. (© Garland Science 2005)



Janeway. Fig. 11.3. Immune evasion via sequential DNA rearrangements of microbial antigens.



Janeway. Fig. 11.3. Immune evasion via sequential DNA rearrangements of microbial antigens. (continued)

Janeway. Fig. 11.5. Immune evasion mechanisms of herpes viruses.

| Viral strategy                 | Specific mechanism                         | Result  | Virus examples                    |
|--------------------------------|--|---|-----------------------------------|
| Inhibition of humoral immunity | Virally encoded Fc receptor                | Blocks effector functions of antibodies bound to infected cells | Herpes simplex<br>Cytomegalovirus |
|                                | Virally encoded complement receptor        | Blocks complement-mediated effector pathways                    | Herpes simplex                    |
|                                | Virally encoded complement control protein | Inhibits complement activation by infected cell                 | Vaccinia                          |

Figure 11-5 part 1 of 3 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 11.5. Immune evasion mechanisms of herpes viruses. (continued)

| Viral strategy                      | Specific mechanism  | Result   | Virus examples                  |
|-------------------------------------|---|--|---------------------------------|
| Inhibition of inflammatory response | Virally encoded chemokine receptor homolog, eg, $\beta$ -chemokine receptor   | Sensitizes infected cells to effects of $\beta$ -chemokine; advantage to virus unknown | Cytomegalovirus                 |
|                                     | Virally encoded soluble cytokine receptor, eg, IL-1 receptor homolog, TNF receptor homolog, interferon- $\gamma$ receptor homolog | Blocks effects of cytokines by inhibiting their interaction with host receptors        | Vaccinia<br>Rabbit myxoma virus |
|                                     | Viral inhibition of adhesion molecule expression, eg, LFA-3 ICAM-1  | Blocks adhesion of lymphocytes to infected cells                                       | Epstein-Barr virus              |
|                                     | Protection from NF $\kappa$ B activation by short sequences that mimic TLRs   | Blocks inflammatory responses elicited by IL-1 or bacterial pathogens                  | Vaccinia                        |

Figure 11-5 part 2 of 3 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 11.5. Immune evasion mechanisms of herpes viruses. (continued)

| Viral strategy                                  | Specific mechanism                        | Result   | Virus examples                    |
|---|---|--|-----------------------------------|
| Blocking of antigen processing and presentation | Inhibition of MHC class I expression      | Impairs recognition of infected cells by cytotoxic T cells                       | Herpes simplex<br>Cytomegalovirus |
|   | Inhibition of peptide transport by TAP    | Blocks peptide association with MHC class I                                      | Herpes simplex                    |
| Immunosuppression of host                       | Virally encoded cytokine homolog of IL-10 | Inhibits T <sub>H</sub> 1 lymphocytes<br>Reduces interferon- $\gamma$ production | Epstein-Barr virus                |

Figure 11-5 part 3 of 3 Immunobiology, 6/e. (© Garland Science 2005)



| Infection with <i>Mycobacterium leprae</i> can result in different clinical forms of leprosy              |   |
|---|---|
| There are two polar forms, tuberculoid and lepromatous leprosy, but several intermediate forms also exist |   |
| Tuberculoid leprosy   | Lepromatous leprosy   |
|                        |  |
| Organisms present at low to undetectable levels   | Organisms show florid growth in macrophages   |
| Low infectivity   | High infectivity  |
| Granulomas and local inflammation. Peripheral nerve damage  | Disseminated infection. Bone, cartilage, and diffuse nerve damage                   |
| Normal serum immunoglobulin levels  | Hypergammaglobulinemia  |
| Normal T-cell responsiveness. Specific response to <i>M. leprae</i> antigens                              | Low or absent T-cell responsiveness. No response to <i>M. leprae</i> antigens       |

Figure 11-6 part 1 of 2 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 11.6. The effect of T helper subpopulations on leprosy outcome.

Janeway. Fig. 11.6. The effect of T helper subpopulations on leprosy outcome. (continued)




Figure 11-6 part 2 of 2 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 14.21. Childhood vaccination schedule in USA.

**Current immunization schedule for children (USA)**

| Vaccine given                           | 1 month                  | 2 months                 | 4 months                 | 6 months                 | 12 months                | 15 months                | 18 months                | 4-6 years                | 11-12 years              | 14-16 years                         |
|---|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------------------------------|
| Diphtheria-tetanus-pertussis (DTP/DTaP) | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| Inactivated polio vaccine               | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>            |
| Measles/mumps/rubella (MMR)             | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>            |
| Pneumococcal conjugate                  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>            |
| Haemophilus B conjugate (HIBc)          | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>            |
| Hepatitis B                             | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>            |
| Varicella                               | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>            |

Figure 14-21 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 14.23.

| Features of effective vaccines |   |
|--------------------------------|---|
| Safe                           | Vaccine must not itself cause illness or death                                |
| Protective                     | Vaccine must protect against illness resulting from exposure to live pathogen |
| Gives sustained protection     | Protection against illness must last for several years                        |

Figure 14-23 part 1 of 2 Immunobiology, 6/e. (© Garland Science 2005)

| Features of effective vaccines |   |
|--------------------------------|---|
| Induces neutralizing antibody  | Some pathogens (such as poliovirus) infect cells that cannot be replaced (eg, neurons). Neutralizing antibody is essential to prevent infection of such cells |
| Induces protective T cells     | Some pathogens, particularly intracellular, are more effectively dealt with by cell-mediated responses  |
| Practical considerations       | Low cost per dose<br>Biological stability<br>Ease of administration<br>Few side-effects   |

Figure 14-23 part 2 of 2 Immunobiology, 6/e. (© Garland Science 2005)

Janeway. Fig. 14.23.  
continued.

## Summary

- Immunity to infection depends on a combination of innate mechanisms (phagocytosis, complement, etc.) and antigen specific adaptive responses (antibody, effector T lymphocytes).
- The immune system regulates which specific responses predominate (humoral vs. cell-mediated) based on the body compartment infected (intracellular vs. extracellular) and on cytokine signals present at initial antigen contact (Th1 vs. Th2 responses).

## Summary-continued

- Disease-causing microbes have virulence mechanisms that resist or evade innate and/or specific immune effector functions.
- Recovery from natural infection or artificial immunization promote specific longterm immunity to re-infection (immunological memory).